Abstract
The significance of STING (encoded by the TMEM173 gene) in tissue inflammation and cancer immunotherapy has been increasingly recognized. Intriguingly, common human TMEM173 alleles R71H-G230A-R293Q (HAQ) and G230A-R293Q (AQ) are carried by ∼60% of East Asians and ∼40% of Africans, respectively. Here, we examine the modulatory effects of HAQ, AQ alleles on STING-associated vasculopathy with onset in infancy (SAVI), an autosomal dominant, fatal inflammatory disease caused by gain-of-function human STING mutations. CD4 T cellpenia is evident in SAVI patients and mouse models. Using STING knock-in mice expressing common human TMEM173 alleles HAQ, AQ, and Q293, we found that HAQ, AQ, and Q293 splenocytes resist STING-mediated cell death ex vivo, establishing a critical role of STING residue 293 in cell death. The HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice did not have CD4 T cellpenia. The HAQ/SAVI(N153S), AQ/SAVI(N153S) mice have more (∼10-fold, ∼20-fold, respectively) T-regs than WT/SAVI(N153S) mice. Remarkably, while they have comparable TBK1, IRF3, and NFκB activation as the WT/SAVI, the AQ/SAVI mice have no tissue inflammation, regular body weight, and normal lifespan. We propose that STING activation promotes tissue inflammation by depleting T-regs cells in vivo. Billions of modern humans have the dominant HAQ, AQ alleles. STING research and STING-targeting immunotherapy should consider TMEM173 heterogeneity in humans.
Teaser
Common human HAQ, AQ TMEM173 alleles dominate the gain-of-function SAVI(N154S) TMEM173 mutant in mice.
Introduction
STING drives cytosolic DNA-induced type I IFNs production 1. Recent research revealed that STING promotes inflammation in a variety of inflammatory diseases, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, kidney injury, neurodegenerative diseases, cardiovascular diseases, obesity, diabetes, and aging 2–9. The type I IFNs-independent function of STING has also emerged 9–12. For example, initially described as a type I interferonopathy 13, recent studies in STING-associated vasculopathy with onset in infancy (SAVI) mouse models showed that SAVI is largely independent of type I IFNs 14–17. In a STING N153S mouse model of SAVI, crossing N153S mice to IRF3/IRF7, and IFNAR1 knockout mice, N153S mice still developed spontaneous lung diseases 14. JAK inhibitors were used to block type I IFNs signaling for SAVI patients with mixed success 17–20. For example, in a review of JAK inhibition in 18 SAVI patients, incomplete response to treatment happened in 7/18 (38%) of patients 21. Furthermore, 2 patients died of respiratory failure despite this treatment 21. Both radioresistant parenchymal and/or stromal cells and hematopoietic cells influence SAVI pathology in mice 22,23. The observation is important because it predicts that allogeneic stem cell transplantation may not work in human SAVI patients. Indeed, lung transplantations did not show improvement in SAVI patients 18,24. Patients died at 3- and 9 months post-lung transplant 18,24. How STING drives inflammation in vivo, independent of type I IFNs, remains unknown. Consequently, there is no curative care for SAVI.
Characterized as an innate immune sensor, STING expression is, paradoxically, high in CD4 T cells 13,25. Furthermore, STING activation kills mouse and human CD4 T cells ex vivo 26–28. SAVI patients and mouse models had CD4 T cellpenia 13,28. STING was first discovered as MPYS for its cell growth inhibition and cell death function in mouse B lymphoma cells 29. STING-mediated cell death is cell type dependent. For example, while STING activation kills human endothelial cells, primary and cancerous T cells, it does not kill mouse MEFs, BMDCs, or BMDMs 30–32. Second, STING-mediated cell death is type I IFNs-independent 28,30,32. Multiple cell death pathways, i.e., apoptosis, necroptosis, pyroptosis, ferroptosis, and PANoptosis, are proposed 32–34. Last, the in vivo biological significance of STING-mediated CD4 T cell death is not clear 28,32. In humans, SAVI patients with constitutively activated STING have low CD4 T cell numbers 13, and type I IFNs are dispensable for STING-mediated human CD4 T cell death 28. Different from SAVI mice, SAVI patients (N154S or V155M) had normal counts of CD8 T and B cells 13.
The human TMEM173 gene is highly heterogeneous 35,36. ∼50% of people in the U.S. carry at least one copy of non-WT TMEM173 allele 35. Among them, the R71H-G230A-R293Q (HAQ) is the 2nd most common TMEM173 allele carried by ∼23% of people in the U.S. 35. However, in East Asians, WT/HAQ (34.3%), not WT/WT (22.0%), is the most common TMEM173 genotype 36. Critically, the HAQ allele was positively selected in modern humans outside Africa 37. Anatomically modern humans outside Africa are descendants of a single Out-of-Africa Migration 50,000∼70,000 years ago. ∼1.4% of Africans have the HAQ allele, while ∼63.9% of East Asians are HAQ carriers 37. Haplotype analysis revealed that HAQ was derived from G230A-R293Q (AQ) allele 37. Importantly, the AQ allele was negatively selected outside Africa 37. ∼40.1% of Africans are AQ carriers, while ∼0.4% of East Asians have the AQ allele 37. TMEM173 alleles often have a dominant negative effect likely because the protein STING exists as a homodimer 29,38. SAVI is an autosomal dominant inflammatory disease 13. WT/HAQ individuals had reduced Pneumovax23®-induced antibody responses compared to WT/WT individuals (NCT02471014) 39. Notably, AQ responds to CDNs and produces type I IFNs in vivo and in vitro 37,40,41, but the AQ allele was negatively selected in non-Africans 37. In contrast, the HAQ allele, defective in CDNs-type I IFNs responses 35,36,39,42,43, was positively selected in non-Africans 37, indicating that the CDNs-type I IFNs independent function of STING was essential for the survival of early modern humans outside of Africa.
In this study, we discovered, surprisingly, that the HAQ, AQ splenocytes are resistant to STING-mediated cell death. We generated HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice and found that the HAQ, AQ alleles prevent CD4 T cellpenia, increasing/restoring T-regs and alleviating/stopping tissue inflammation in SAVI mice, thus providing evidence for the in vivo significance of type I IFNs-independent, STING-mediated cell death and potential AQ-based curative therapy for SAVI patients.
Results
STING activation kills mouse spleen CD4, CD8 T, and CD19 B cells ex vivo
We first used the synthetic non-CDNs STING agonist diABZI 44 to induce lymphocyte death because diABZI induces cell death without the need for lipid transfection or detergent for cell permeabilization 31,45 and diABZI is in clinical trials (NCT05514717). Splenocytes from C57BL/6N mice were treated with diABZI in culture, and cell death was determined by Annexin V and Propidium Iodide stain. Splenocyte cell death could be detected as early as 5 hours post diABZI treatment (Figure S1A). Dosage responses showed that ∼25ng/ml diABZI could kill 70% of splenocytes (Figure S1B). Similarly, STING agonists DMXAA and synthetic CDNs RpRpss-Cyclic di-AMP killed mouse spleen CD4, CD8 T cells, and CD19 B cells (Figure 1A). Thus, STING activation readily induces mouse lymphocyte death ex vivo.
TBK1 activation is required for STING-mediated mouse spleen cell death ex vivo
STING activation can lead to apoptosis, pyroptosis, necroptosis, or ferroptosis 28–34,45,46. We then treated mouse splenocytes with apoptosis, pyroptosis, necroptosis inhibitors, STING inhibitors H-151, C-176, and palmitoylation inhibitor 2-bromopalmitate (2-BP), followed by diABZI stimulation. Inhibitors for NLRP3 (MCC950), RIPK1 (Necrostatin-1), RIPK3 (GSK872), Caspase-1 (VX-795), Caspase-3 (Z-DEVD-FMK), Caspase 1,3,8,9 (Q-VD-Oph), ferroptosis (liproxstatin-1) did not affect diABZI-induced splenocyte cell death ex vivo (Figure S1B, S1C). The STING inhibitors H-151, C-176, and 2-BP also could not prevent diABZI-induced cell death (Figure S1C) though they inhibited diABZI-induced IFNβ production (Figure S1D). Instead, the TBK1 inhibitor BX-795 abolished diABZI-induced splenocyte death (Figure S1C).
BX-795 is a multi-kinase inhibitor, including 3-phosphoinositide-dependent protein kinase 1 (PDK1) and TBK1 (IC50s = 6 and 11 nM, respectively). However, the treatment of PDK1 inhibitor GSK2334470 (IC50 = 10nM) did not prevent diABZI-induced splenocyte death (Figure 1B). In contrast, GSK8612, a highly potent and selective inhibitor for TBK1, prevented diABZI-induced splenocyte death (Figure 1B). Thus, TBK1 activation is likely critical for STING-mediated splenocyte cell death ex vivo.
HAQ, AQ, Q293 STING knock-in mouse splenocytes are resistant to STING-mediated cell death ex vivo
HAQ and AQ are common human TMEM173 alleles 35–37. Previously, we reported that HAQ knock-in mice are defective in CDNs-induced immune responses, while CDNs responses in AQ knock-in mice are similar to WT mice 37. We treated splenocytes from HAQ and AQ mice with diABZI ex vivo and found, surprisingly, that both HAQ and AQ splenocytes were resistant to diABZI-induced cell death (Figure 1C, 1D). In comparison, IFNAR1-/- splenocytes were killed by diABZI, confirming that STING-mediated lymphocytes death are type I IFNs-independent (Figure 1C, 1D) 28,30,32.
HAQ and AQ share the common A230 and Q293 residues changes. We thus generated a Q293 TMEM173 knock-in mouse. Notably, the Q293 splenocytes were resistant to STING agonists 2’3’-cGAMP, RpRpss-Cyclic di-AMP, and diABZI-induced cell death (Figure 1E, 1F). Thus, the residue 293 of STING is critical for its cell death function.
WT/HAQ, WT/AQ mouse splenocytes are partially resistant to STING-mediated cell death ex vivo
WT/HAQ (34.3%) is the most common human TMEM173 genotype in East Asians, while WT/AQ (28.2%) is the 2nd most common TMEM173 genotype in Africans 36. We generated WT/HAQ, WT/AQ mice and treated their splenocytes with mouse STING agonist DMXAA. WT/HAQ and WT/AQ splenocytes were protected from 25µg/ml DMXAA-induced cell death (Figure 1G). 100µg/ml DMXAA could kill WT/HAQ and WT/AQ splenocytes, albeit less than WT/WT cells (Figure 1G). Thus, the HAQ and AQ alleles are dominant and likely impact STING activation even in heterozygosity.
STING activation kills primary human CD4 T cells but not CD8 T or CD19 B cells
STING agonists-based clinical trials in humans have been disappointing (NCT02675439, NCT03010176, NCT05514717) 47,48. We showed that the human TMEM173 gene might undergo natural selection during the out-of-Africa migration 37 sensitive to evolutionary pressure. Thus, we investigated STING-mediated death in primary human lymphocytes.
Human explant lung cells from the WT(R232)/WT(R232) donors were treated with STING agonists 2’3-c GAMP, RpRpss-Cyclic di-AMP, diABZI for 24 hours in culture. Lymphocyte cell death was determined by Propidium Iodide staining. Different from mouse lymphocytes, diABZI and RpRpss-Cyclic di-AMP killed human CD4 T but not CD8 T or CD19 B cells (Figure 2A, 2B). Human CD8 T and CD19 B cells are resistant to 500ng/ml diABZI-induced cell death (Figure S2A).
WT/HAQ human CD4 T cells are resistant to low doses of diABZI-induced cell death
WT/HAQ mouse splenocytes are resistant to low-dose diABZI-induced cell death (Figure 1G). To extend our observation into primary human T cells, we obtained lung explants from WT/WT and WT/HAQ individuals (Figure S2B) and treated them with diABZI in culture. 25ng/ml diABZI killed WT/WT, but not WT/HAQ, human lung CD4 T cells (Figure 2C).
diABZI induces cell death in STING-KO human THP-1 cells reconstituted with WT human STING (R232) but not HAQ, AQ or Q293 human STING allele
To further determine cell death influenced by human TMEM173 alleles HAQ, AQ, and Q293, we used the STING-KO THP-1 cell line because STING agonist induces type I IFNs and cell death in STING-KO THP-1 cells expressing WT human STING 34 (Figure S2C, S2D). We, thus, generated stable THP-1 STING-KO lines expressing HAQ, AQ, WT, or Q293 TMEM173 allele. Cell death was determined by Annexin-V staining. diABZI killed THP-1 STING-KO lines expressing WT but not HAQ, AQ, or Q293 TMEM173 allele (Figure 2D, 2E). No cell death was induced in the Q293 THP-1 cells stimulated by 20 to 200 ng/ml of diABZI (Figure 2F). diABZI also did not induce STING activation in Q293 THP-1 cells (Figure 2G). Notably, 50ng/ml diABZI induced p-IRF3 activation and type I IFNs in AQ THP-1 cells but not HAQ THP-1 cells (Figure 2H, 2I), indicating that the STING-cell death and STING-IRF3-Type I IFNs pathways can be uncoupled.
HAQ and AQ alleles rescue the lymphopenia and suppress myeloid cell expansion in SAVI(N153S) mice.
The in vivo significance of the STING/MPYS-cell death is unclear. Furthermore, multiple cell death pathways, i.e., apoptosis, necroptosis, pyroptosis, ferroptosis, and PANoptosis, are proposed 32–34. The uncertainty likely results from studies using different cell types (primary cells vs cancer cell lines); species (human vs mouse); STING agonists (cGAMP, which requires cell permeabilization by detergents or lipid transfection, vs diABZi, DMXAA that can directly cross the membrane) 26,27,30,31,49. Critically, which mechanism is relevant in vivo, causing T cellpenia is not known. To clarify the in vivo significance and mechanisms of STING-mediated cell death, we turned to SAVI mice.
SAVI is an autosomal dominant, inflammatory disease caused by one copy of a gain-of-function TMEM173 mutant (WT/SAVI) 13. CD4 T cellpenia was found in SAVI patients and SAVI mouse models 13,14. STING activation in SAVI mice is independent of ligands and happens in vivo. We thus generated HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice aiming to establish the in vivo significance and mechanism of STING-cell death.
First, HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice had reduced splenomegaly compared to WT/SAVI(N153S) mice though their spleens were still larger than the littermates WT/HAQ and WT/AQ (Figure 3A, 3B). Next, HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice had similar spleen B cells and CD4 T cell numbers as the WT/HAQ, WT/AQ littermates (Figure 2B, 2C). Their CD8+ T cells were lower than their WT littermates but much higher than the WT/SAVI(N153S) mice (Figure 3D). Third, spleen myeloid cell numbers, i.e., neutrophils, Ly6Chi monocytes and F4/80 macrophages, were all reduced by half compared to WT/SAVI(N153S) mice (Figure 3E∼3H). Last, splenocytes from HAQ/SAVI, AQ/SAVI mice were partially resistant to diABZI, DMXAA-induced cell death ex vivo (Figure S3). Notably, the HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice also had restored bone marrow monocytes (Figure S4). Thus, HAQ and AQ alleles prevent lymphopenia and suppress myeloid cell expansion in SAVI(N153S) mice.
The HAQ allele alleviates and the AQ allele prevents SAVI(N153S) disease in mice
SAVI(N153S) disease is characterized by early onset, failure to thrive (low body weight), persistent lung inflammation, decreased lung function, and young death in humans and mouse models 13,17,49,50. The HAQ/SAVI(N153S) mice weighed more and had an improved lifespan than the WT/SAVI(N153S) mice (Figure 4A, 4B). The lifespan, airway resistance, and tissue inflammation (lung, liver) were also improved in HAQ/SAVI(N153S) mice compared to the WT/SAVI(N153S) mice (Figure 4C, 4D, 4J, 4K). However, the pulmonary artery pressure was still elevated in HAQ/SAVI(N153S) mice (Figure 4E). Remarkably, the AQ/SAVI(N153S) mice had similar body weight and lifespan as the WT/AQ mice (Figure 4F, 4G). The airway resistance, pulmonary artery pressure, and tissue inflammation in AQ/SAVI(N153S) were similar to the WT/AQ littermates (Figure 4H, 4I, 4J, 4K). Thus, the HAQ allele alleviates and the AQ allele prevents inflammatory SAVI disease in mice. Interestingly, lungs from HAQ/SAVI, AQ/SAVI had similarly reduced infiltration of Ly6G+CD11B+ neutrophils and Ly6G-Ly6C+CD11B+ inflammatory monocytes compared to WT/SAVI mice (Figure S5).
diABZI induces similar STING, TBK1, IRF3, NFκB activation in the AQ/SAVI(N153S) and WT/SAVI(N153S) bone-marrow-derived-macrophage (BMDM)
SAVI was characterized as type I interferonopathy 17. However, several studies showed that type I IFN signaling and IRF3 activation were dispensable for SAVI disease 14,15,23,50. AQ allele prevents SAVI disease (Figure 4). However, diABZI-treated AQ/SAVI(N153S) and WT/SAVI(N153S) BMDM had similar TBK1-IRF3 activation and IFNβ production (Figure 5A, 5B). diABZI treatment caused IκBα degradation, and similar TNF production in WT/SAVI and AQ/SAVI BMDM (Figure 5C, 5D). Furthermore, diABZI activation led to STING protein degradation in WT/SAVI and AQ/SAVI BMDM (Figure 5E). Last, using cleavable crosslinker dithiobis (succinimidyl propionate (DSP), we showed that STING in WT/SAVI, AQ/SAVI BMDM forms a similar dimer in situ (Figure 5F). Thus, the AQ/SAVI BMDM had similar STING degradation, TBK1, IRF3, NFκB activation, and dimerization as the WT/SAVI BMDM.
The HAQ allele increased, and the AQ allele restored T-regs in SAVI(N153S) mice
IFNγ was proposed to drive SAVI disease 15,23,38. We confirmed that WT/SAVI CD4 T cells were enriched with IFNγ+ cells (Figure 6A). However, WT/SAVI mice have CD4 T cellpenia. Thus, the total numbers of spleen IFNγ+ CD4 T cells were comparable in WT/SAVI and AQ/SAVI mice (Figure 6A). In contrast, the HAQ/SAVI mice had decreased IFNγ+ CD4 T cells (Figure 6A).
The induction of Foxp3 expression in T-reg cells during ongoing autoimmune inflammation resolved inflammation and pathology in mice 51. CD4 T cellpenia depletes CD4 T-regs. Indeed, WT/SAVI mice had ∼20-fold reduction of spleen FoxP3+ T-regs compared to AQ/SAVI or WT/WT littermates (Figure 6B). The HAQ/SAVI mice also had ∼10-fold more T-regs than the WT/SAVI littermate (Figure 6B).
Discussion
This study, using the HAQ, AQ, SAVI(N153S) TMEM173 knock-in mice, reveals the in vivo significance and mechanism of STING-mediated CD4 T cell death. HAQ, AQ alleles prevent CD4 T cellpenia, and increase/restore CD4 T-regs in SAVI mice. The results are consistent with previous finding that the impaired CD4 T cell proliferation by the SAVI(V155M) mutant could be rescued by the addition of the HAQ allele in vitro 27. STING has been increasingly implicated in inflammatory diseases such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, cardiomyopathy, obesity, diabetes, neurodegenerative diseases, aging, and kidney injury, many of which are independent of type I IFNs 2,3,9. It is tempting to suggest that STING activation in CD4 T cells leads to CD4 T-regs depletion that break tissue tolerance and exacerbates tissue inflammation.
Human immunodeficiency virus (HIV) primarily infects CD4 T cells and might activate the STING pathway in CD4 T cells 52–57. The loss of CD4 T cells is the hallmark of untreated HIV infection 58,59, and the measurement of CD4 T cell count is a central part of HIV care. We found that HAQ and AQ CD4 T cells are resistant to STING-mediated cell death. Mogensen and colleagues reported that HAQ/HAQ was enriched in HIV-infected long-term nonprogressors 42. These HAQ/HAQ individuals had reduced inhibition of CD4 T cell proliferation and a reduced immune response to DNA and HIV 42. It is likely that HIV infection activates STING-cell death pathway in CD4 T cells. In HAQ/SAVI and AQ/SAVI mice, one copy of HAQ, AQ allele suppressed CD4 T cell death. HAQ, AQ carriers might have fewer HIV-induced CD4 T cell death, thus being long-term nonprogressors in HIV infection-induced Acquired immunodeficiency syndrome (AIDS)42. Targeting STING to prevent CD4 T cell death might be a valid therapy for AIDS. Activating the STING pathway is a promising strategy for cancer immunotherapy 60–66.
Multiple STING agonists are in clinical trials 47,48. Recently, the safety issue emerged in some STING agonist trials 47,48. For example, in the STING agonist, ADU-S100, clinical trial, Grade 3/4 treatment-related adverse events were reported in 12.2% of 41 pretreated patients (NCT02675439)47,48. The National Institutes of Health defines grade 3 as “incapacitating; unable to perform usual activities; requires absenteeism or bed rest.” In a clinical trial using STING antibody-drug-conjugate (ADC) that conjugates diABZI to anti-HER2 Ab, a Grade 5 (fatal) serious adverse event was recorded and deemed related to the STING-ADC (NCT05514717). SAVI disease, driven by overreacting STING, is often fatal13. AQ, to a less degree, HAQ, suppress mortality in SAVI mice. Future STING clinical trials should be based on human TMEM173 genotype to achieve safe and effective responses.
Mechanistically, apoptosis, pyroptosis, ferroptosis, necroptosis, and PANoptosis have all been reported in STING-mediated cell death 28–34,45,46. Different cell types and STING agonists used likely contributed to the inconsistency and complexity. Here, we focused on lymphopenia in the SAVI mice that avoids ligand-dependent, non-physiological dosage in STING-mediated cell death. HAQ and AQ alleles could prevent CD4 T cellpenia in the SAVI mice strongly indicating that residue A230 or Q293 prevent STING-mediated CD4 T cell death in vivo. Splenocyte from Q293 mice were resistant to STING agonists-induced cell death ex vivo. Thus, it is likely that the Q293 residue is critical for STING-mediate lymphopenia. Notably, Q293 is outside the C-terminal tail (CTT) (residues 341–379 of human STING) critical for TBK1 recruitment and IRF3 phosphorylation 67 or miniCTT domain (aa343–354) 27, or the UPR motif (aa322–343) 49 important for T cells death in vitro. Further studies are needed to understand how the aa293 of STING mediates cell death in vivo. Noteworthy, AQ/SAVI cells had similar TBK1-IRF3, NFκB activation and STING degradation as the WT/SAVI cells. Yet, AQ/SAVI mice did not have CD4 T cellpenia as WT/SAVI mice suggesting that the canonical STING-TBK1-IRF3/NFκB pathway, likely STING oligomerization, is not sufficient for the induction of cell death at the physiological condition.
We used the WT/N153S knock-in SAVI mouse model that spontaneously develop lung inflammation, T cell cytopenia, and early mortality, mimicking pathological findings in human SAVI patients16. Using the WT/N153S SAVI mouse model and human Jurkat T cell line, it was proposed that STING activation causes chronic ER stress and unfolded protein response, leading to T cell death by apoptosis 49. Furthermore, the study showed that crossing WT/N153S mice to the OT-I mice reduced ER stress and restored CD8+, but not CD4+, T cells 49. The restoration of CD8+T cells reduces inflammation and lung disease 49. However, human WT/N154S SAVI patients have normal CD8+ T cells numbers 13, and primary human CD8+ T cells are largely resistant to STING-agonists-induced cell death ex vivo (Figure 2A) 28. Thus, it is puzzling how restoring CD8+ T cells can rescue SAVI phenotypes since the SAVI patients already have normal CD8+ T cells numbers.
Finally, it is unexpected that both HAQ and AQ alleles are resistant to cell death. Our previous studies showed that the HAQ and AQ alleles have opposite functions 37. AQ-STING, not HAQ-STING, responds to CDNs 35–37,39–43,68. AQ mice are lean while HAQ mice are fat 37. Most importantly, HAQ was positively selected, while AQ was negatively selected, in modern humans outside Africans 37. Thus, the death pathway of STING is also distinct from the STING function that was naturally selected. It is worth noting that the AQ allele does better than the HAQ allele in suppressing SAVI disease. Thus, besides preventing cell death, additional mechanism by the AQ allele, e.g. fatty acid metabolism 37,69, is involved in curing SAVI.
The limitations of the study
The poor transferability of mouse to humans is a major issue in STING research 47,48. The present study used AQ/SAVI and HAQ/SAVI mice. Confirmation is needed in humans with the identification and evaluation of people who are AQ/SAVI, HAQ/SAVI.
Materials and Methods
Experimental Design
The study was designed to reveal (i) the in vivo significance of the type I IFNs-independent, STING-dependent cell death function; (ii) the interplay between common STING alleles HAQ, AQ and the rare, gain-of-function SAVI STING mutation; (iii) the driver for the inflammatory SAVI disease. Mouse splenocytes, primary human lung cells, human THP-1 cells and HAQ, AQ, SAVI knock-in mice were used to establish the in vivo significance and human relevance. All the repeats were biological replications that involve the same experimental procedures on different mice. Where possible, treatments were assigned blindly to the experimenter by another individual in the lab. When comparing samples from different groups, samples from each group were analyzed in concert, thereby preventing any biases that might arise from analyzing individual treatments on different days. All experiments were repeated at least twice.
Mice
WT/SAVI(N153S) mice were purchased from The Jackson Laboratory. HAQ, AQ mice were previously generated in the lab 36,37. The Q293 mice were generated by Cyagen Biosciences. Briefly, the linearized targeting vector was transfected into JM8A3.N1 C57BL/6N embryonic stem cells. A positive embryonic stem clone was subjected to the generation of chimera mice by injection using C57BL/6J blastocysts as the host. Successful germline transmission was confirmed by PCR sequencing. The heterozygous mice were bred to Actin-flpase mice [The Jackson Laboratory, B6.Cg-Tg (ACTFLPe)9205Dym/J] to remove the neo gene and make the Q293 knock-in mouse. Age-and gender-matched mice (2 – 6 month old, both male and female) were used for indicated experiments. WT/SAVI (male) x WT/HAQ (female), WT/SAVI (male) x WT/AQ (female) breeders were set up to generate HAQ/SAVI, AQ/SAVI mice. Mice were housed at 22°C under a 12-h light-dark cycle with ad libitum access to water and a chow diet (3.1 kcal/g, Teklad 2018, Envigo, Sommerset, NJ) and bred under pathogen-free conditions in the Animal Research Facility at the University of Florida. Littermates of the same sex were randomly assigned to experimental groups. All mouse experiments were performed by the regulations and approval of the Institutional Animal Care and Use Committee at the University of Florida, IACUC202200000058.
Reagents
Recombinant human IFNβ (R&D, cat no. 8499-IF-010/CF), diABZI (Invivogen, cat no. 2138299-34-8), 2’3’-cGAMP (Invivogen, cat no. tlrl-nacga23-02), DMXAA (Invivogen, cat no. tlrl-dmx), H151 (Invivogen, cat no. inh-h151), RpRpSS-Cyclic di-AMP (Biolog, cat no. C118), THP1-Dual™ KO-STING Cells (Invivogen, cat no. thpd-kostg). All other chemical inhibitors are from Selleckchem. Mouse TNF alpha ELISA Ready Set Go. (eBioscience, cat no. 88-7324). Mouse IFN-Beta ELISA Kit (PBI, cat no. 42400).
Generation of THP-1 KO-STING cells stably expressing human TMEM173 alleles
THP1-Dual™ KO-STING Cells in 6-well plate were transfected with 1µg TMEM173 plasmid (in pcDNA 3.1 vector) with Lipofectamine LTX and Plus Reagent (Invitrogen, cat no: A12621) according to the manufacturer’s instructions. Transfecting Plasmid DNA into THP-1 Cells Using Lipofectamine LTX Reagent | Thermo Fisher Scientific - US. 48hrs after the transfection, the cell medium was changed. G418 (1mg/ml) was added to the culture to select STING expressing THP-1 cells. The G418-resistant cells were established and expanded.
Histology
Lungs and livers were fixed in 10% formalin, paraffin-embedded, and cut into 4-µm sections. Lung, liver sections were then stained for hematoxylin-eosin. All staining procedures were performed by the histology core at the University of Florida. Briefly, tissue sectins were immersed Harris Hematoxylin for 10 seconds, then washed with tap water. Cleard sections were re-immersed in EOSIN stain for ∼30 seconds. The sections were washed with tap water until clear, then dehydrate in ascending alcohol solutions (50%,70%,80%,95% x 2, 100% x 2). Afterwards, the sections werer cleared with xylene (3 - 4 x). The sections were mounted on glass slide with permount organic mounting medium for visulization.
Lung Function
Pulmonary function was evaluated using an isolated, buffer-perfused mouse lung apparatus (Hugo Sachs Elektronik, March-Huggstetten, Germany), as previously described 70. Briefly, mice were anesthetized with ketamine and xylazine and a tracheostomy was performed, and animals were ventilated with room air at 100 breaths/min at a tidal volume of 7 μl/g body weight with a positive end-expiratory pressure of 2 cm H2O using a pressure-controlled ventilator (Hugo Sachs Elektronik, March-Huggstetten, Germany).
Isolation of lung cells
Cells were isolated from the lung as previously described 71. The lungs were perfused with ice-cold PBS and removed. Lungs were digested in DMEM containing 200μg/ml DNase I (Roche, 10104159001), 25μg/ml Liberase TM (Roche, 05401119001) at 37°C for 2 hours. Red blood cells were then lysed and a single cell suspension was prepared by filtering through a 70-µm cell strainer.
BMDM activation
BMDMs were induced from mouse bone marrow cells cultured in RPMI 1640 (cat#11965; Invitrogen) with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES buffer, 1% nonessential amino acids, 50 mM 2-ME, 1% Pen/Strep, with 20ng/ml M-CSF (Kingfisher, RP0407M) for 10 days 36. STING agonists were added into the culture (no transfection or membrane permeabilization).
Flow cytometry
Single cell suspensions were stained with fluorescent-dye-conjugated antibodies in PBS containing 2% FBS and 1mM EDTA. Surface stains were performed at 4°C for 20 min. For intracellular cytokine or transcription factor staining of murine and human cells, cells were fixed and permeabilized with the Foxp3 staining buffer set (eBioscience, cat no 00-5523-00). Cells were washed and stained with surface markers. Cells were then fixed and permeabilized (eBioscience, cat no. 00-5523-00) for intracellular cytokine stain. Data were acquired on a BD LSRFortessa and analyzed using the FlowJo software package (FlowJo, LLC). Cell sorting was performed on the BD FACSAriaIII Flow Cytometer and Cell Sorter. More information on the antibodies used can be found in supplementary table S1.
Human lung explants
Human lung explants were procured at the Lung Transplant Center, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida. Donor and patients consent was obtained for a research protocol (UF IRB201902955-Treatment with IFNβ Induces Tolerogenic Lung Dendritic Cells in Human advanced lung disease). Healthy donor lungs were surgically removed postmortem, perfused, small pieces were cut from the right middle and lower lobes for research purpose, and stored in cold Perfadex ® at 4°C for no more than 12 hrs before processing. Ex planted lungs from emphysema lung transplant patients were stored in cold Perfadex ® at 4°C for no more than 12 hrs before the process. No lung explants were procured from prisoners.
Statistical Analysis
To gain statistical power, we employ three∼four mice/groups to characterize lung immunity. Ten mice/group to monitor animal health. The statistical justification for group size was calculated using the SAS program to calculate the animal numbers. The analysis was carried out using a standard error of 0.5 for immunological assays, and a power of 0.9. All data are expressed as means ± SEM. Statistical significance was evaluated using Prism 9.0 software. Comparisons between two groups were analyzed by performing an unpaired Student’s t test. Comparisons between more than two groups were analyzed by performing a one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test.
Acknowledgements
Funding
National Institutes of Health grant HL152163 (L.J.).
Competing interests
Authors declare that they have no competing interests.
Data and materials availability
All data are available in the main text or the supplementary materials.
Supplementary Materials
References
- 1STING: infection, inflammation and cancerNat Rev Immunol 15:760–770
- 2Role of the cGAS-STING pathway in systemic and organ-specific diseasesNat Rev Nephrol 18:558–572
- 3cGASSTING signaling and function in metabolism and kidney diseasesJ Mol Cell Biol 13:728–738
- 4Mini review: STING activation during non-alcoholic fatty liver diseaseFront Nutr 10
- 5cGAS-STING drives ageing-related inflammation and neurodegenerationNature 620:374–380
- 6Constitutively active STING causes neuroinflammation and degeneration of dopaminergic neurons in miceElife 11
- 7STING/ACSL4 axis-dependent ferroptosis and inflammation promote hypertension-associated chronic kidney diseaseMol Ther
- 8Mitochondrial damage and activation of the cytosolic DNA sensor cGAS-STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy miceCell Death Discov 8
- 9Type-1 interferon-dependent and -independent mechanisms in cyclic GMP-AMP synthase-stimulator of interferon genes-driven auto-inflammationCurr Opin Immunol 80
- 10Interferon-independent STING signaling promotes resistance to HSV-1 in vivoNat Commun 11
- 11Interferon-Independent Activities of Mammalian STING Mediate Antiviral Response and Tumor Immune EvasionImmunity 53:115–126
- 12Non-Interferon-Dependent Role of STING Signaling in Pulmonary HypertensionArterioscler Thromb Vasc Biol 44:124–142
- 13Activated STING in a vascular and pulmonary syndromeN Engl J Med 371:507–518
- 14STING-associated lung disease in mice relies on T cells but not type I interferonJ Allergy Clin Immunol 144:254–266
- 15.The IFN-gamma receptor promotes immune dysregulation and disease in STING gain-of-function miceJCI Insight 7
- 16STING-associated vasculopathy develops independently of IRF3 in miceJ Exp Med 214:3279–3292
- 17Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 PatientsJ Allergy Clin Immunol Pract 9:803–818
- 18A 17-Year-Old Girl Diagnosed With STING-Associated Vasculopathy With Onset in Infancy (SAVI) After Lung TransplantationChest 162:e249–e252
- 19Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI SyndromeJ Clin Immunol 39:476–485
- 20STING-Associated Vasculopathy with Onset in Infancy in Three Children with New Clinical Aspect and Unsatisfactory Therapeutic Responses to TofacitinibJ Clin Immunol 40:114–122
- 21Stimulator of Interferon Genes-Associated Vasculopathy With Onset in Infancy: A Systematic Review of Case ReportsFront Pediatr 8
- 22Endothelial cell expression of a STING gain-of-function mutation initiates pulmonary lymphocytic infiltrationCell Rep 43
- 23Radioresistant cells initiate lymphocyte-dependent lung inflammation and IFNgamma-dependent mortality in STING gain-of-function miceProc Natl Acad Sci U S A 119
- 24Severe Pulmonary Fibrosis as the First Manifestation of Interferonopathy (TMEM173 Mutation)Chest 150:e65–71
- 25STING/MPYS mediates host defense against Listeria monocytogenes infection by regulating Ly6C(hi) monocyte migrationJ Immunol 190:2835–2843
- 26Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell DeathJ Immunol 199:397–402
- 27Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytesJ Exp Med 214:1769–1785
- 28STING agonism turns human T cells into interferon-producing cells but impedes their functionalityEMBO Rep 24
- 29MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signalsMol Cell Biol 28:5014–5026
- 30Signalling strength determines proapoptotic functions of STINGNat Commun 8
- 31Signal strength of STING activation determines cytokine plasticity and cell death in human monocytesSci Rep 12
- 32Crosstalk between cGAS-STING signaling and cell deathCell Death Differ 27:2989–3003
- 33STING1 Promotes Ferroptosis Through MFN1/2-Dependent Mitochondrial FusionFront Cell Dev Biol 9
- 34SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosisSci Rep 12
- 35Identification and characterization of a loss-of-function human MPYS variantGenes Immun 12:263–269
- 36The Common R71H-G230A-R293Q Human TMEM173 Is a Null AlleleJ Immunol 198:776–787
- 37MPYS Modulates Fatty Acid Metabolism and Immune Tolerance at Homeostasis Independent of Type I IFNsJ Immunol 209:2114–2132
- 38TMEM173 variants and potential importance to human biology and diseaseGenes Immun 20:82–89
- 39Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacyJCI Insight 5
- 40Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotidesPLoS One 8
- 41Response to Comment on “The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele”J Immunol 198:4185–4188
- 42Multiple Homozygous Variants in the STING-Encoding TMEM173 Gene in HIV Long-Term NonprogressorsJ Immunol 200:3372–3382
- 43The common HAQ STING variant impairs cGAS-dependent antibacterial responses and is associated with susceptibility to Legionnaires’ disease in humansPLoS Pathog 14
- 44Design of amidobenzimidazole STING receptor agonists with systemic activityNature 564:439–443
- 45STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS)Cell Death Dis 13
- 46Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B CellsCancer Res 76:2137–2152
- 47Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib StudyClin Cancer Res 29:110–121
- 48Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or LymphomasClin Cancer Res 28:677–688
- 49STING-mediated disruption of calcium homeostasis chronically activates ER stress and primes T cell deathJ Exp Med 216:867–883
- 50Hierarchy of clinical manifestations in SAVI N153S and V154M mouse modelsProc Natl Acad Sci U S A 116:7941–7950
- 51Regulatory T cells function in established systemic inflammation and reverse fatal autoimmunityNat Immunol 22:1163–1174
- 52IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIVScience 343:428–432
- 53Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infectionNature 505:509–514
- 54Innate immune sensing of HIV-1 infectionCurr Opin HIV AIDS 10:96–102
- 55Innate immune sensing of HIV infectionCurr Opin Immunol 32:54–60
- 56Innate immunity against HIV-1 infectionNat Immunol 16:554–562
- 57STING dependent sensing - Does HIV actually care?Cytokine Growth Factor Rev 40:68–76
- 58CD4(+) T cell signatures in HIV infectionNat Immunol 20:948–950
- 59Altered differentiation is central to HIV-specific CD4(+) T cell dysfunction in progressive diseaseNat Immunol 20:1059–1070
- 60The Development of STING Agonists and Emerging Results as a Cancer ImmunotherapyCurr Oncol Rep 25:189–199
- 61The cGAS-STING pathway and cancerNat Cancer 3:1452–1463
- 62STING, a promising target for small molecular immune modulator: A reviewEur J Med Chem 211
- 63Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapyMol Cancer 19
- 64Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and ImmunityCell Rep 11:1018–1030
- 65STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockadeSci Transl Med 7
- 66Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responsesCurr Opin Immunol 23:10–20
- 67Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activationScience 347
- 68Interplay between human STING genotype and bacterial NADase activity regulates inter-individual disease variabilityNat Commun 14
- 69STING orchestrates the crosstalk between polyunsaturated fatty acid metabolism and inflammatory responsesCell Metab 34:125–139
- 70MicroRNA-206 antagomiRenriched extracellular vesicles attenuate lung ischemiareperfusion injury through CXCL1 regulation in alveolar epithelial cellsJ Heart Lung Transplant 39:1476–1490
- 71Lung IFNAR1(hi) TNFR2(+) cDC2 promotes lung regulatory T cells induction and maintains lung mucosal tolerance at steady stateMucosal Immunol 13:595–608
Article and author information
Author information
Version history
- Preprint posted:
- Sent for peer review:
- Reviewed Preprint version 1:
- Reviewed Preprint version 2:
- Version of Record published:
Copyright
© 2024, Aybar-Torres et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.